Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 2315.HK files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.28% | 30.00% | Pass |
| Interest-bearing investments | 6.58% | 30.00% | Pass |
| Non-permissible income | 0.31% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.94% | 33.00% | Pass |
| Interest-bearing investments | 41.97% | 33.00% | Fail |
| Non-liquid assets | 49.97% | at least 20.00% | Pass |
| Non-permissible income | 0.31% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.94% | 33.33% | Pass |
| Cash + interest-bearing securities | 41.97% | 33.33% | Fail |
| Accounts receivable | 50.03% | 33.33% | Fail |
| Non-permissible income | 0.31% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.94% | 33.33% | Pass |
| Cash + interest-bearing securities | 41.97% | 33.33% | Fail |
| Accounts receivable | 50.03% | 50.00% | Fail |
| Non-permissible income | 0.31% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.09% | 33.00% | Pass |
| Cash + interest-bearing securities | 14.20% | 33.00% | Pass |
| Accounts receivable | 2.73% | 33.00% | Pass |
| Non-permissible income | 0.31% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 9.10% | 33.00% | Pass |
| Cash + interest-bearing securities | 18.23% | 49.00% | Pass |
| Accounts receivable | 3.50% | 49.00% | Pass |
| Non-permissible income | 0.31% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 9.10% | 33.33% | Pass |
| Cash + interest-bearing securities | 18.23% | 33.33% | Pass |
| Accounts receivable | 21.73% | 49.00% | Pass |
| Non-permissible income | 0.31% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 47.30 | NEUTRAL |
| Stochastic %K (14) | 19.90 | BUY |
| CCI (20) | -89.18 | NEUTRAL |
| Williams %R (14) | -80.10 | BUY |
| MACD (12,26,9) | -0.63 | SELL |
| ROC (10) | -3.49 | SELL |
| Momentum (10) | -2.10 | SELL |
| EMA (10) | 60.40 | SELL |
| SMA (10) | 60.24 | SELL |
| EMA (20) | 60.42 | SELL |
| SMA (20) | 61.44 | SELL |
| EMA (30) | 59.59 | SELL |
| SMA (30) | 61.19 | SELL |
| EMA (50) | 57.62 | SELL |
| SMA (50) | 57.31 | SELL |
| EMA (100) | 53.95 | BUY |
| SMA (100) | 52.60 | BUY |
| EMA (200) | 47.61 | BUY |
| SMA (200) | 48.35 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; engages in breeding and selling animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; engages un utilizing the Group's own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and engages in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.